Cantor Fitzgerald Estimates BCRX FY2026 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of BioCryst Pharmaceuticals in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the biotechnology company will post earnings of $0.21 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $20.00 price objective on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share.

A number of other brokerages also recently issued reports on BCRX. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 22nd. JPMorgan Chase & Co. increased their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an “overweight” rating in a report on Tuesday, May 6th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Needham & Company LLC increased their price target on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday, May 6th. Finally, Wedbush began coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price target for the company. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $16.56.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $11.01 on Tuesday. The company has a market cap of $2.30 billion, a P/E ratio of -18.05 and a beta of 1.11. The firm’s fifty day moving average is $9.15 and its two-hundred day moving average is $8.33. BioCryst Pharmaceuticals has a 52-week low of $5.92 and a 52-week high of $11.31.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Headlands Technologies LLC bought a new position in BioCryst Pharmaceuticals during the 1st quarter valued at about $32,000. GF Fund Management CO. LTD. bought a new position in BioCryst Pharmaceuticals during the 4th quarter valued at about $33,000. GAMMA Investing LLC grew its holdings in BioCryst Pharmaceuticals by 1,161.8% during the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,449 shares during the last quarter. Venturi Wealth Management LLC bought a new position in BioCryst Pharmaceuticals during the 4th quarter valued at about $46,000. Finally, New Age Alpha Advisors LLC bought a new position in BioCryst Pharmaceuticals during the 1st quarter valued at about $62,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.